Business
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery,
About this update from Crinetics Pharmaceuticals, Inc.
[{"type":"text","content":"SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Rogério Vivaldi Coelho, M.D., M.B.A. to the company’s board of directors. Dr. Vivaldi comes to Crinetics with over two decades of experience as a physician and industry executive with deep expertise commercializing pharmaceuticals, especially those treating rare and orphan diseases, in the U.S. and globally. Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, stated, “Dr. Vivaldi’s expertise in global commercial operations, coupled with his passion for meeting the needs of patients with rare diseases, make him a natural fit for Crinetics. As we advance our expanding portfolio of novel therapeutics for multiple rare endocrine diseases, we are looking forward to leveraging his skills and experience building commercial enterprises to ensure we are prepared to deliver treatments to patients worldwide.” Dr. Vivaldi is currently the president and chief executive officer of Sigilon Therapeutics, Inc., where he also serves as a member of the company's board of directors. Prior to joining Sigilon, Dr. Vivaldi served as executive vice president and chief global therapeutics officer at Bioverativ Inc., where he was responsible for building and managing their commercial organization, including sales and marketing efforts for the franchise’s lead products, until it was acquired by Sanofi S.A. in 2018. He also previously served as chief commercial officer at Spark Therapeutics, Inc., where he spearheaded the launch of global commercial operations, and patient advocacy, market access, and medical affairs efforts for Luxturna. Earlier, he held several positions of increasing responsibility over a 20-year career at Genzyme, most recently serving as the head of the company’s rare disease business, president of both the rare disease business and the renal & endocrine group, and as senior vice president and general manager of its Latin America group. During his time at Genzyme, he led the successful approval of more than 15 orphan products in more than 20 countries. Dr. Vivaldi earned a medical degree from the Universidade ...